4.8 Article

MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis

Journal

NATURE GENETICS
Volume 40, Issue 10, Pages 1175-1184

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ng.226

Keywords

-

Funding

  1. Intramural NIH HHS [Z01 DK043308, Z01 DK043308-12] Funding Source: Medline
  2. NCI NIH HHS [N01CO12400, N01-CO-12400] Funding Source: Medline
  3. NIDDK NIH HHS [R01 DK072348, R01 DK072348-04, R01 DK067528-05, R01 DK070941, R01 DK059997-04, R01 DK059997, ZO-1 DK043308] Funding Source: Medline

Ask authors/readers for more resources

The increased burden of chronic kidney and end-stage kidney diseases (ESKD) in populations of African ancestry has been largely unexplained. To identify genetic variants predisposing to idiopathic and HIV-1-associated focal segmental glomerulosclerosis (FSGS), we carried out an admixture-mapping linkage-disequilibrium genome scan on 190 African American individuals with FSGS and 222 controls. We identified a chromosome 22 region with a genome-wide logarithm of the odds (lod) score of 9.2 and a peak lod of 12.4 centered on MYH9, a functional candidate gene expressed in kidney podocytes. Multiple MYH9 SNPs and haplotypes were recessively associated with FSGS, most strongly a haplotype spanning exons 14 through 23 (OR = 5.0, 95% CI 3.5-7.1; P = 4 x 10(-23), n = 852). This association extended to hypertensive ESKD (OR = 2.2, 95% CI = 1.5-3.4; n = 433), but not type 2 diabetic ESKD (n 476). Genetic variation at the MYH9 locus substantially explains the increased burden of FSGS and hypertensive ESKD among African Americans.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available